不同时长的FOLFOX辅助化疗方案治疗高危Ⅱ~Ⅲ期结肠癌患者的疗效及预后分析  

Efficacy and prognosis of patients with high-risk stage Ⅱ~Ⅲ colon cancer treated by FOLFOX adjuvant chemotherapy with different duration

作　　者：刘秋月 黄德峰[1] 李利安[1] LIU Qiuyue;HUANG Defeng;LI Li’an(Department of Gastroenterology,Luohe Central Hospital,Luohe 462000,He’nan,China)

机构地区：[1]漯河市中心医院消化内科,河南漯河462000

出　　处：《癌症进展》2022年第16期1697-1700,共4页Oncology Progress

摘　　要：目的探讨不同时长的奥沙利铂+亚叶酸钙+氟尿嘧啶(FOLFOX)辅助化疗方案治疗高危Ⅱ~Ⅲ期结肠癌患者的疗效及预后。方法依据治疗方案的不同将90例高危Ⅱ~Ⅲ期结肠癌术后患者分3M组(接受3个月FOLFOX辅助化疗方案,45例)和6M组(接受6个月FOLFOX辅助化疗方案,45例)。比较两组患者的临床疗效、血清肿瘤标志物[碱性成纤维细胞生长因子(bFGF)和恶性肿瘤相关物质群(TSGF)]水平、生活质量[欧洲癌症研究与治疗组织生命质量测定量表(EORTC QLQ-C30)]、不良反应发生率及生存情况。结果两组患者的总有效率比较,差异无统计学意义(P﹥0.05)。治疗后,两组患者的血清bFGF、TSGF水平均低于本组治疗前(P﹤0.05);治疗后,两组患者的血清b FGF、TSGF水平比较,差异均无统计学意义(P﹥0.05)。治疗后,两组患者EORTC QLQ-C30各维度评分均高于本组治疗前(P﹤0.05);治疗后,两组患者EORTC QLQ-C30各维度评分比较,差异均无统计学意义(P﹥0.05)。3M组患者的不良反应总发生率低于6M组患者(P﹤0.05)。两组患者的3年无瘤生存率和3年总生存率比较,差异均无统计学意义(P﹥0.05)。结论高危Ⅱ~Ⅲ期结肠癌患者接受3个月和6个月FOLFOX辅助化疗后均具有较好的疗效和预后,生活质量均可获得有效提高,但3个月FOLFOX辅助化疗方案的不良反应更少,患者耐受性更佳。Objective To explore the efficacy and prognosis of patients with high risk stage Ⅱ~Ⅲ colon cancer treated by oxaliplatin+calcium folinate+fluorouracil(FOLFOX)adjuvant chemotherapy with different duration.Method A total of 90 patients with high risk stage Ⅱ~Ⅲ colon cancer were divided into 3M group(n=45,treated with FOLFOX adjuvant chemotherapy for 3 months)and 6M group(n=45,treated with FOLFOX adjuvant chemotherapy for 6 months).The clinical efficacy,serum tumor markers[basic fibroblast growth factor(bFGF),tumor supplied group of factor(TSGF)],quality of life[European Organization for Research and Treatment of Cancer quality of life questionnaire core-30(EORTC QLQ-C30)],incidence of adverse reactions and survival between the two groups were compared.Result There was no significant difference for the total effective rate between the two groups(P>0.05).After treatment,the levels of serum bFGF and TSGF in the two groups were lower than those before treatment(P<0.05),without significant difference between the two groups(P>0.05).After treatment,each dimensional scores of EORTC QLQ-C30 in the two groups were higher than those before treatment,without significant difference between the two groups(P>0.05).The total incidence of adverse reactions in 3M group was significantly lower than that in 6M group(P<0.05),but there were no significant differences in 3-year disease-free survival rate and 3-year overall survival rate between the two groups(P>0.05).Conclusion For patients with high risk stage Ⅱ~Ⅲ colon cancer,3 and 6 months of FOLFOX adjuvant chemotherapy can achieve significant efficacy and prognosis,the quality of life is improved,but the 3M regimen group has fewer adverse reactions and better tolerance.

关 键 词：Ⅱ~Ⅲ期结肠癌 FOLFOX 临床疗效 血清肿瘤标志物 辅助化疗 生活质量 不良反应 

分 类 号：R735.35[医药卫生—肿瘤]